CEO Sabrina Martucci Johnson announced the company's intent to make its proprietary Sildenafil Cream formulation available by prescription through a 503B-registered outsourcing facility in Q4 2025.

The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...